Cynata’s Cymerus™ MSCs Effective in Preclinical Model of Diabetic Wounds
June 01, 2018 08:00 ET
|
Cynata Therapeutics Limited
MELBOURNE, Australia, June 01, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX:CYP) is pleased to announce that it has received...
$5.2m placement of shares to Fidelity International
May 30, 2018 09:31 ET
|
Cynata Therapeutics Limited
MELBOURNE, Australia, May 30, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP) (‘Cynata’) is pleased to announce a A$5.2 million...
Enrolment Completed in Cynata’s Phase 1 Clinical Trial of CYP-001 in GvHD
May 24, 2018 08:00 ET
|
Cynata Therapeutics Limited
MELBOURNE, Australia, May 24, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX:CYP) is pleased to announce that the final patient has...
Cynata Therapeutics Completes Patent Application to Cover Cymerus™ Stem Cell Technology in the Treatment of Side Effects Related to CAR-T Therapy
April 20, 2018 07:00 ET
|
Cynata Therapeutics Limited
Initial data from preclinical study at the University of Massachusetts Amherst demonstrate Cymerus MSCs ameliorate the effects of cytokine release syndrome (CRS) and other related adverse reactions to...
Cynata to Present at the Preeminent Cell & Gene Therapy Investor Day in New York
April 12, 2018 13:04 ET
|
Cynata Therapeutics Limited
MELBOURNE, Australia, April 12, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP), is pleased to announce that it has been...
FDA Grants Orphan Drug Designation to Cynata’s Lead Cymerus™ MSC Product, CYP-001
March 28, 2018 08:00 ET
|
Cynata Therapeutics Limited
MELBOURNE, Australia, March 28, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX:CYP) is pleased to announce that the United States...
Excellent Cohort A Data From Final Primary Evaluation Period in Cynata GvHD Phase 1 Clinical Trial
February 27, 2018 08:00 ET
|
Cynata Therapeutics Limited
MELBOURNE, Australia, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP) is pleased to announce that the Primary...
Treatment Commences in Second Patient Cohort in Cynata’s World First Clinical Trial
January 24, 2018 08:00 ET
|
Cynata Therapeutics Limited
MELBOURNE, Australia, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP), is pleased to announce that the first patient...
Cynata Executes MoU for Commercial Evaluation with Celularity, Inc.
January 23, 2018 10:05 ET
|
Cynata Therapeutics Limited
MoU signed with Celularity, Inc. for the evaluation of and identification of commercial opportunities for the CymerusTM platform and Celularity’s leading cell therapy assetsFollows...
Encouraging Early Safety and Efficacy Data in Cynata’s Phase 1 Trial of CYP-001 in GvHD; DSMB Recommendation to Initiate Enrolment of Second Patient Cohort
January 22, 2018 08:00 ET
|
Cynata Therapeutics Limited
MELBOURNE, Australia, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP) is pleased to announce that the independent Data...